XFOR X4 Pharmaceuticals, Inc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501697 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY73.7%
TTM net income YoY15.3%
TTM EPS YoY106.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin68.8%
Operating margin-812.0%
Net margin-813.3%
FCF margin—
EBITDA margin-794.1%
Returns
ROE-80.3%
ROA-40.7%
ROIC (approx.)-134.7%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets40.1%
Debt / equity0.54x
Current ratio13.22x
Interest coverage-9.26x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-2.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6.50M | $2.60M | $0 | $0 | $0 |
| Cost of revenue | $5.76M | $797,000 | $0 | $0 | — |
| Gross profit | $743,000 | $1.80M | $0 | $0 | — |
| R&D expense | $72.72M | $81.64M | $72.02M | $61.06M | $50.65M |
| SG&A expense | $43.52M | $61.52M | $35.51M | $27.02M | $24.70M |
| Operating income | -$86.88M | -$36.40M | -$107.52M | -$87.57M | -$85.11M |
| Interest expense | $8.88M | $8.77M | $5.78M | $3.99M | $3.64M |
| Pretax income | -$79.16M | -$37.14M | -$101.09M | -$93.84M | -$88.68M |
| Income tax | $41,000 | $310,000 | $78,000 | $28,000 | $17,000 |
| Net income | -$79.20M | -$37.45M | -$101.17M | -$93.87M | -$88.70M |
| EBITDA | -$85.61M | -$35.60M | -$107.10M | -$87.06M | -$84.61M |
| EPS (basic) | -1.87 | -5.59 | -17.07 | -1.52 | -3.99 |
| EPS (diluted) | -1.87 | -5.59 | -17.07 | -1.52 | -3.99 |
| Weighted avg. shares (diluted) | 42.29M | 6.70M | 5.93M | 63.53M | 25.75M |
| Balance sheet | |||||
| Cash & equivalents | $217.05M | $56.48M | $100.25M | $123.03M | $83.11M |
| Receivables | $573,000 | $1.07M | $0 | — | — |
| Inventory | $4.48M | $2.82M | $0 | — | — |
| Current assets | $261.58M | $112.17M | $122.08M | $128.68M | $87.88M |
| PP&E, net | $182,000 | $776,000 | $745,000 | $1.10M | $1.51M |
| Goodwill | $17.35M | $17.35M | $17.35M | $17.35M | $17.35M |
| Intangibles | $9.25M | $10.00M | $0 | — | — |
| Total assets | $290.46M | $146.45M | $147.26M | $155.59M | $117.18M |
| Current liabilities | $25.76M | $32.88M | $22.86M | $22.32M | $14.02M |
| Short-term debt | — | — | $0 | $1.31M | $795,000 |
| Long-term debt | $75.00M | $75.00M | $55.00M | $32.30M | $33.14M |
| Total debt | $75.00M | $75.00M | $55.00M | $33.62M | $33.93M |
| Total liabilities | $104.17M | $124.30M | $96.16M | $81.53M | $52.76M |
| Shareholders' equity | $186.29M | $22.15M | $51.10M | $74.05M | $64.41M |
| Net debt | -$142.05M | $18.52M | -$45.25M | -$89.41M | -$49.17M |
| Shares outstanding | 90.91M | 5.70M | 167.43M | 121.67M | 28.13M |
| Cash flow statement | |||||
| Operating cash flow | -$85.62M | -$130.90M | -$96.51M | -$77.10M | -$70.91M |
| Capital expenditure | $0 | $326,000 | $60,000 | $103,000 | $615,000 |
| Free cash flow | -$85.62M | -$131.23M | -$96.57M | -$77.20M | -$71.52M |
| Investing cash flow | $8.15M | $66.99M | -$14.88M | -$103,000 | -$615,000 |
| Financing cash flow | $238.63M | $20.29M | $88.52M | $117.23M | $74.25M |
| Depreciation & amortization | $1.28M | $796,000 | $419,000 | $513,000 | $499,000 |
| Stock-based compensation | $4.30M | $8.20M | $8.69M | $5.20M | $6.18M |
| Share buybacks | — | — | $0 | $0 | $2.00M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.